Mascoma Wealth Management LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 7.2% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 8,196 shares of the company’s stock after buying an additional 554 shares during the quarter. Johnson & Johnson makes up about 0.7% of Mascoma Wealth Management LLC’s investment portfolio, making the stock its 24th largest position. Mascoma Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,066,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Harding Loevner LP bought a new position in Johnson & Johnson in the 2nd quarter worth $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its holdings in Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after buying an additional 200 shares during the period. Mountain Capital Investment Advisors Inc bought a new position in Johnson & Johnson in the 2nd quarter worth $124,000. Shine Investment Advisory Services Inc. bought a new position in Johnson & Johnson in the 2nd quarter worth $177,000. Finally, Lenox Wealth Management Inc. boosted its holdings in Johnson & Johnson by 1.7% in the 2nd quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock worth $193,000 after buying an additional 24 shares during the period. 65.53% of the stock is owned by institutional investors.

Shares of Johnson & Johnson (JNJ) opened at $130.27 on Tuesday. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. The stock has a market cap of $349,970.00, a PE ratio of 334.03, a PEG ratio of 2.33 and a beta of 0.74. Johnson & Johnson has a 1 year low of $115.22 and a 1 year high of $148.32.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.02. The firm had revenue of $20.20 billion for the quarter, compared to analysts’ expectations of $20.08 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. The business’s revenue was up 11.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.58 EPS. sell-side analysts anticipate that Johnson & Johnson will post 8.08 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 2.58%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s dividend payout ratio is 861.54%.

Several research firms have commented on JNJ. Stifel Nicolaus increased their price objective on shares of Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a report on Wednesday, October 18th. JPMorgan Chase & Co. downgraded shares of Johnson & Johnson from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 2nd. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 price objective for the company in a report on Wednesday, December 20th. BMO Capital Markets increased their price objective on shares of Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th. Finally, BTIG Research reissued a “sell” rating and set a $110.00 price objective on shares of Johnson & Johnson in a report on Wednesday, January 24th. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Johnson & Johnson has a consensus rating of “Hold” and an average price target of $146.16.

COPYRIGHT VIOLATION WARNING: “Johnson & Johnson (JNJ) Position Lifted by Mascoma Wealth Management LLC” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.thecerbatgem.com/2018/02/13/johnson-johnson-jnj-position-lifted-by-mascoma-wealth-management-llc.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.